We dhould remember that DMD affects the skeleton of the brain resulting lower intellectual performance.
ATL1102 has been used to treat MS so it does cross blood brain barrier.
May it also improve CNS issues?
- Forums
- ASX - By Stock
- Ann: First Patient Dosed in ATL1102 Phase IIb DMD Trial
We dhould remember that DMD affects the skeleton of the brain...
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.5¢ |
Change
0.001(1.19%) |
Mkt cap ! $76.63M |
Open | High | Low | Value | Volume |
8.4¢ | 8.5¢ | 8.4¢ | $28.30K | 335.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 306394 | 8.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.6¢ | 181214 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 40444 | 0.085 |
2 | 306394 | 0.084 |
1 | 10000 | 0.083 |
2 | 193598 | 0.082 |
2 | 49037 | 0.081 |
Price($) | Vol. | No. |
---|---|---|
0.087 | 234229 | 3 |
0.088 | 13868 | 1 |
0.089 | 14285 | 1 |
0.090 | 546175 | 2 |
0.091 | 108000 | 1 |
Last trade - 14.08pm 19/06/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
INF
INFINITY LITHIUM CORPORATION LIMITED
Ryan Parkin, Managing Director & CEO
Ryan Parkin
Managing Director & CEO
Previous Video
Next Video
SPONSORED BY The Market Online